RecruitingPhase 2NCT07491458

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

A Parallel Treatment Group, Phase 2a, Double-blind, 4-arm Trial to Evaluate the Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Male and Female Participants Aged 30 Years or Older With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Sponsor

Rivus Pharmaceuticals, Inc.

Enrollment

180 participants

Start Date

Feb 13, 2026

Study Type

INTERVENTIONAL

Conditions

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Summary

Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also assess safety, pharmacokinetics (PK) and changes in liver fat content related to patients diagnosed with MASH.

Eligibility

Min Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HU6 and Placebo for people with mash - metabolic dysfunction-associated steatohepatitis. The study is currently recruiting participants at 31 locations. People eligible for this study include aged 30 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHU6

HU6 is being evaluated for efficacy in MASH

OTHERPlacebo

Placebo comparator

Locations(31)

Arizona Liver Health - Chandler

Chandler, Arizona, United States

Arizona Liver Health - Peoria

Peoria, Arizona, United States

Arizona Liver Health - Tucson

Tucson, Arizona, United States

Baptist Health Center for Clinical Research

Little Rock, Arkansas, United States

National Institute of Clinical Research

Garden Grove, California, United States

Catalina Research Institute

Montclair, California, United States

Knowledge Research Center

Orange, California, United States

Charter Research LLC - Orlando

Orlando, Florida, United States

Charter Research LLC - Chicago

Chicago, Illinois, United States

Delta Research Partners of Bastrop, LLC

Bastrop, Louisiana, United States

Delta Research Partners of West Monroe, LLC

West Monroe, Louisiana, United States

Clinical Research Institute of Michigan

Clinton Township, Michigan, United States

Nucleus Network Minneapolis

Saint Paul, Minnesota, United States

Kansas City Research Institute

Kansas City, Missouri, United States

KAD Clinical Research

St Louis, Missouri, United States

Jubilee Clinical Research, LLC.

Las Vegas, Nevada, United States

Coastal Research Institute

Fayetteville, North Carolina, United States

Clinical Research Institute of Ohio, LLC (CRIOH)

Westlake, Ohio, United States

Tekton Research - Yukon

Yukon, Oklahoma, United States

Innovative Clinical Research, LLC

Clarksville, Tennessee, United States

IMA Clinical Research (Austin)

Austin, Texas, United States

Pinnacle Clinical Research - Austin

Austin, Texas, United States

Bellaire Clinical Research, LLC

Bellaire, Texas, United States

Pinnacle Clinical Research - Corpus Christi

Corpus Christi, Texas, United States

Pinnacle Clinical Research - Georgetown

Georgetown, Texas, United States

HRI - Medical Center, LLC

Houston, Texas, United States

Houston Research Institute

Houston, Texas, United States

HRI - Pasadena, LLC

Pasadena, Texas, United States

Quality Research

San Antonio, Texas, United States

Pinnacle Clinical Research - San Antonio

San Antonio, Texas, United States

HRI - Sugarland, LLC

Sugar Land, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07491458

Related Trials

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314323 locations

Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer

NCT068249741 location

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

NCT0733560117 locations

Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

NCT0763267722 locations

A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

NCT0730380317 locations